GlaxoSmithKline receives WHO prequalification for new Synflorix dosing option

GlaxoSmithKline has announced that its pneumococcal vaccine Synflorix has been awarded World Health Organization (WHO) prequalification for a new dosing option.

The world health body has given the green light to a four-dose vial presentation of Synflorix, which is targeted mainly at countries that receive support from Gavi, an international organisation created to improve access to vaccines in poorer nations.

WHO helps to ensure that vaccines secured through Unicef for use in national immunisation services in low and middle-income countries have an appropriate safety and efficacy profile, and are suitable for the target populations.

Synflorix's four-dose vial presentation has a cold-chain volume of 2.4 cubic cm per dose, the lowest of any pneumococcal conjugate vaccine. This reduces the physical space required for storage, while also allowing more children to be vaccinated per vial compared to the existing two-dose vial presentation.

Thomas Breuer, chief medical officer at GlaxoSmithKline Vaccines, said: "Through this presentation, we are committed to expanding access to children in Gavi countries where the need is greatest."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.